OPTIMIZING NON-ADDICTIVE DRUG DELIVERY WORLDWIDE
IN THE MANAGEMENT OF PAIN AND CNS DISORDERS
Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery systems across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate.
Our transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to optimize the efficacy of our non-addictive pain management pipeline and our CNS disorder pipeline.
Virpax® Pharmaceuticals (Nasdaq: VRPX) is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.
OPTIMIZING DRUG-DELIVERY
In the Treatment of Pain and CNS Disorders
Envelta™
Molecular Envelope Enkephalin Powder
Envelta is an intranasal enkephalin powder formulation being studied to manage severe post cancer pain and non-cancer pain without the concerns of dependence, respiratory depression, and tolerance compared to morphine.
Probudur™
Injectable liposomal hydrogel Bupivacaine
Virpax will introduce its proprietary Probudur, a single injectable liposomal gel local anesthetic for postoperative pain management. Probudur will be the only liposomal gel bupivacaine with 96 hours of postoperative pain control; longer than any other liposomal bupivacaine.
Recent Media
OUR MISSION
Our mission is to use our proprietary delivery systems to optimize the efficacy of our non‑addictive pain and CNS disorder product candidates.
We want to provide healthcare professionals and patients with effective solutions to manage pain and neurological disorders worldwide.
